Literature DB >> 29299463

Surrogate end points in early prostate cancer clinical states: ready for implementation?

Christos E Kyriakopoulos1, Emmanuel S Antonarakis2.   

Abstract

Entities:  

Year:  2017        PMID： 29299463      PMCID： PMC5750273          DOI： 10.21037/atm.2017.10.25

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  15 in total

1.  Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.

Authors:  Richard K Valicenti; Michelle DeSilvio; Gerald E Hanks; Arthur Porter; Harmar Brereton; Seth A Rosenthal; William U Shipley; Howard M Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-18       Impact factor: 7.038

2.  Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

Authors:  William U Shipley; Wendy Seiferheld; Himanshu R Lukka; Pierre P Major; Niall M Heney; David J Grignon; Oliver Sartor; Maltibehn P Patel; Jean-Paul Bahary; Anthony L Zietman; Thomas M Pisansky; Kenneth L Zeitzer; Colleen A F Lawton; Felix Y Feng; Richard D Lovett; Alexander G Balogh; Luis Souhami; Seth A Rosenthal; Kevin J Kerlin; James J Dignam; Stephanie L Pugh; Howard M Sandler
Journal:  N Engl J Med       Date:  2017-02-02       Impact factor: 91.245

3.  Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial.

Authors:  James W Denham; Allison Steigler; Chantelle Wilcox; David S Lamb; David Joseph; Chris Atkinson; John Matthews; Keen-Hun Tai; Nigel A Spry; David Christie; Paul S Gleeson; Peter B Greer; Catherine D'Este
Journal:  Lancet Oncol       Date:  2008-10-15       Impact factor: 41.316

4.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Authors:  Howard I Scher; Michael J Morris; Walter M Stadler; Celestia Higano; Ethan Basch; Karim Fizazi; Emmanuel S Antonarakis; Tomasz M Beer; Michael A Carducci; Kim N Chi; Paul G Corn; Johann S de Bono; Robert Dreicer; Daniel J George; Elisabeth I Heath; Maha Hussain; Wm Kevin Kelly; Glenn Liu; Christopher Logothetis; David Nanus; Mark N Stein; Dana E Rathkopf; Susan F Slovin; Charles J Ryan; Oliver Sartor; Eric J Small; Matthew Raymond Smith; Cora N Sternberg; Mary-Ellen Taplin; George Wilding; Peter S Nelson; Lawrence H Schwartz; Susan Halabi; Philip W Kantoff; Andrew J Armstrong
Journal:  J Clin Oncol       Date:  2016-02-22       Impact factor: 44.544

5.  The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).

Authors:  Christopher Sweeney; Mari Nakabayashi; Meredith Regan; Wanling Xie; Julia Hayes; Nancy Keating; Suhui Li; Tomas Philipson; Marc Buyse; Susan Halabi; Philip Kantoff; A Oliver Sartor; Howard Soule; Brandon Mahal
Journal:  J Natl Cancer Inst       Date:  2015-09-25       Impact factor: 13.506

6.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

7.  Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.

Authors:  Hossein Jadvar; Bhushan Desai; Lingyun Ji; Peter S Conti; Tanya B Dorff; Susan G Groshen; Mitchell E Gross; Jacek K Pinski; David I Quinn
Journal:  Clin Nucl Med       Date:  2012-07       Impact factor: 7.794

8.  Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

Authors:  Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

9.  Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.

Authors:  Michael E Ray; Kyounghwa Bae; Maha H A Hussain; Gerald E Hanks; William U Shipley; Howard M Sandler
Journal:  J Natl Cancer Inst       Date:  2009-02-10       Impact factor: 13.506

10.  Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy.

Authors:  M T Schweizer; X C Zhou; H Wang; T Yang; F Shaukat; A W Partin; M A Eisenberger; E S Antonarakis
Journal:  Ann Oncol       Date:  2013-08-14       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.